Market Fallers: GlaxoSmithKline plc, Shire PLC &WPP PLC

GlaxoSmithKline plc

The share price for GlaxoSmithKline plc company symbol: LON:GSK has dropped -1.52% or -23.6 points during the course of today’s session so far. Investors were not positive during the trading session. The periods high has already touched 1538.4 and a low of 1515.2. The total volume of shares exchanged through this period comes to 2,285,847 whilst the daily average number of shares exchanged is just 8,771,049. The 52 week high for the shares is 1631.13 some 78.53 points difference from the previous days close and putting the 52 week low at 1179.39 which is a variance of 373.21 points. GlaxoSmithKline plc has a 20 day moving average of 1524.77 and now the 50 day SMA of 1546.15. The market capitalisation is now £75,845.74m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for GlaxoSmithKline plc being recorded at Thursday, October 25, 2018 at 11:59:52 AM GMT with the stock price trading at 1529 GBX.

 

Shares of Shire PLC ticker lookup code: LON:SHP has declined -3.27% or -146.5 points in today’s trading session so far. Traders were not positive during the trading session. The periods high has already touched 4395 dipping to 4323.5. Volume total for shares traded during this period was 1,217,837 while the average shares exchanged is 2,604,514. A 52 week share price high is 4662 which comes in at 177 points difference from the previous close and the 52 week low at 2940.5 which is a variance of 1544.5 points. Shire PLC now has a 20 moving average of 4506.45 and now the 50 day SMA of 4494.46. The market capitalisation currently stands at £40,001.40m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for Shire PLC being recorded at Thursday, October 25, 2018 at 11:59:50 AM GMT with the stock price trading at 4338.5 GBX.

 

The share price for WPP PLC with EPIC code: LON:WPP has declined -16.67% or -176 points during the course of today’s session so far. Sellers have so far given a mostly negative outlook while the stock has been in play. The periods high figure was 905 while the low for the session was 818. The number of shares traded by this point in time totalled 11,265,344 whilst the daily average number of shares exchanged is just 6,083,819. A 52 week high for the stock is 1474.25 amounting to 418.25 points in difference to the previous days close of business and a 52 week low sitting at 818 a difference of some 238 points. WPP PLC has a 20 SMA of 1100.23 and now a 50 day SMA of 1171.54. The market capitalisation is now £17,246.46m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for WPP PLC being recorded at Thursday, October 25, 2018 at 11:59:55 AM GMT with the stock price trading at 880 GBX.

Share on:
Find more news, interviews, share price & company profile here for:

    GSK Plc completes acquisition of IDRx, Inc.

    GSK plc has completed its acquisition of IDRx, Inc., aiming to advance treatments for gastrointestinal stromal tumours with the novel IDRX-42 inhibitor.

    GSK Plc 5-in-1 meningococcal vaccine approved by FDA

    GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates.

    GSK Plc reports strong growth in Specialty Medicines and R&D progress

    GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns.

    GSK plc Depemokimab applications accepted for review in China and Japan

    GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results.

    GSK Plc Shingrix new prefilled syringe presentation accepted for review by EMA

    GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe.

    GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment

    GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates.

      Search

      Search